Date: 2015-03-03
Type of information: Distribution agreement
Compound: OncoDEEP DX, Package PLUS and Clinical cancer panels
Company: OncoDNA (Belgium) Biosequence (Spain)
Therapeutic area: Cancer - Oncology
Type agreement: distribution
Action mechanism: theranostic analyses
Disease:
Details: * On March 3, 2015, OncoDNA, a belgian cancer theranostic company, which performs DNA next generation sequencing (NGS) and molecular pathology (IHCs) to provide oncologists with drug treatment recommendations, has recently finalized a distribution agreement with BioSequence,
the leading personalized cancer genomics provider in Spain to bring affordable and state-of-theart theranostic analyses to the Spanish population.
BioSequence has chosen OncoDNA as its preferred supplier of clinical grade molecular theranostic using the OncoDEEP DX and Clinical cancer panels in combination with the Package PLUS, a cancer specific package of different IHCs and other tests designed to analyse key proteins’ presence and activity, translocations, etc. The collaboration agreement with OncoDNA will enable Spanish physicians to access medical innovations based on next gen sequencing, providing them with clinically relevant interpretations of patients\' tumors by using the OncoSHARE web platform designed by OncoDNA. This collaboration agreement confers distribution exclusivity in Spain for BIOSEQUENCE. This is the ninth exclusive agreement granted by OncoDNA.
Financial terms:
Latest news:
